Share this Page:
Scientists at the Dana-Farber Cancer Institute in Boston, USA, are testing a new personalised cancer vaccine, called NeoVax, for the treatment of kidney cancer patients at high risk of recurrence following surgery.
The vaccine incorporates proteins (neoantigens) that are specific to the cancer cells in each individual’s tumour. The vaccine is then linked to a checkpoint inhibitor, called ipilimumab, which boosts the immune system to attack the cancer cells. When introduced into the body, the personalised vaccine guides the immune system to attack cancer cells containing these specific neoantigens.
